Stock Analiz

Nexalin Technology, Inc. NXL

Biotechnology: Electromedical & Electrotherapeutic Apparatus · IPO 2022 · data as of November 13, 2026

$1.48Market cap $2M
Open the interactive analysis →

Nexalin Technology, Inc. (NXL) is a healthcare company listed in the US with a market value of about $2M. In the twelve months to September 30, 2026 it had revenue of $277307 and net income of -$9M, a net margin of -3380.6%.

Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is track record (0/5).

Key numbers: a P/E of 0.2, a 5-year average ROIC of -127%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 64% below the current price.

About Nexalin Technology

Nexalin Technology is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus, IPO year 2022. Revenue went from $144065 in 2021 to $301647 in 2025, growth of about 20.3% a year. It was profitable in 0 of the last 5 years in our data. Its share count rose by 194% over three years (dilution for shareholders). It spends 359% of revenue on research and development.

Score: 1.8 / 5

Value2/5
Future growth3/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)0.2
Forward P/E—
P/FCF—
P/S6.6
P/B6.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−64%

Growth and quality

Revenue growth (1 yr)78.8%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-3155.9%
ROIC (5-yr avg.)-126.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 5 years

Fiscal yearTTM20252024202320222021
Revenue$277307$301647$168721$110748$1M$144065
Net income-$9M-$8M-$8M-$5M-$2M-$6M
Free cash flow————-$2M-$1M
EPS (diluted)$7.07$-0.50$-0.83$-0.63$-0.30—
Net margin-3380.6%-2725.8%-4508.7%-4197.6%-128.5%-4218.9%
ROIC—-176.9%-166.7%-140.1%-24.0%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $15.00, 914% above the current price; targets range from $15.00 to $15.00; the consensus rating is “none”; expected EPS is $-11.42 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Nexalin Technology’s P/E ratio?

About 0.2, based on the last twelve months of diluted earnings per share.

Is Nexalin Technology stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 64% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Nexalin Technology pay a dividend?

Not currently.

Is Nexalin Technology a good stock to buy?

We do not give buy or sell advice. Nexalin Technology scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.